Discover a study examining epinephrine for anaphylaxis safety, highlighting cardiovascular risks, correct dosing, and why ...
The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against ...
MedPage Today on MSN
Nasal Spray Epinephrine Increasingly Used in the Office
Intranasal epinephrine was administered within 1 minute of identifying the reaction or when the patient returned to the ...
ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy® (epinephrine nasal spray) Oral presentation to report results from real ...
The Healthy @Reader's Digest on MSN
“What I Wish I’d Known About Allergic Anaphylaxis”: A Patient’s Story, with an Expert Doctor’s Insights
Despite his best effort to check food labels, one college student details his close call with anaphylaxis and what he learned ...
Offers no-hassle, free virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with commercial insurance Program is available to eligible patients who may ...
WARREN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement ...
Older adults with anaphylaxis had higher rates of drug and venom triggers than younger adults and were more frequently admitted to the ICU. They received less epinephrine and were less likely to have ...
Detailed price information for Ars Pharmaceuticals Inc (SPRY-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback